modelR01AD02

Extends from Pharmacokinetic.Models.PK_2C_enteral.

Information

name:Prednisolone
ATC code:R01AD02
route:oral
compartments:2
dosage:20mg
volume of distribution:61L
clearance:7.5L/h
other parameters in model implementation

Prednisolone is a synthetic glucocorticoid, used for its anti-inflammatory and immunosuppressive effects in the treatment of a variety of conditions including allergies, asthma, autoimmune diseases, and certain types of cancer. It is an approved and commonly used medication in clinical practice.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers (both sexes) following oral administration.

References

  1. de Truchis, C, et al., & Boyer, O (2023). Prednisolone pharmacokinetics after oral prednisone administration in paediatric patients with kidney transplant. British journal of clinical pharmacology 89(5) 1532–1540. DOI:10.1111/bcp.15610 PUBMED:https://pubmed.ncbi.nlm.nih.gov/36510685

  2. Petersen, KB, et al., & Schmiegelow, K (2003). Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia. Cancer chemotherapy and pharmacology 51(6) 465–473. DOI:10.1007/s00280-003-0602-3 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12698270

  3. Yoshida, K, et al., & Chanu, P (2021). Population Pharmacokinetics of Ipatasertib and Its Metabolite in Cancer Patients. Journal of clinical pharmacology 61(12) 1579–1591. DOI:10.1002/jcph.1942 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34273118

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance
Pharmacolibrary.Types.TransferRateka (from PK_2C_enteral)0.016666666666666666first order absorption rate
Modelica.Units.SI.TimeTlag (from PK_2C_enteral)600delay between oral administration and absorption (default 10min)

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)